Trials / Recruiting
RecruitingNCT06110403
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
Impact of Inhaled BGF 160 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Multicentre, prospective, non-randomised, single-arm, open label, mechanistic study to investigate the mechanism of action of BGF 160 on ventilation pattern complexity and variability
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRIXEO AEROSPHERE | BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days. |
Timeline
- Start date
- 2023-09-29
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2023-10-31
- Last updated
- 2025-12-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06110403. Inclusion in this directory is not an endorsement.